Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AZTR | US
0.11
60.59%
Healthcare
Biotechnology
30/06/2024
20/03/2026
0.28
0.33
0.38
0.26
Azitra Inc a pre-clinical biopharmaceutical company focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12 a genetically modified strain of S. epidermidis for treating Netherton syndrome a skin disease; ATR-04 a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01 an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris a skin disease. The company was incorporated in 2014 and is based in Branford Connecticut.
View LessStrength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
340.0%1 month
241.6%3 months
169.1%6 months
137.6%0.01
-
2.42
0.42
0.19
-0.39
10.02
-
-10.12M
2.16M
2.16M
-
-35.47K
-
-95.60
-222.30
0.78
3.18
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.28
Range1M
0.28
Range3M
0.28
Rel. volume
17.71
Price X volume
141.36M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vaccinex Inc - Ordinary Shares | VCNX | Biotechnology | 0.888 | 2.31M | -28.39% | n/a | -4.26% |
| Dermata Therapeutics Inc. Common Stock | DRMA | Biotechnology | 1.46 | 2.20M | 20.66% | n/a | 0.00% |
| Sorrento Therapeutics Inc | SRNE | Biotechnology | 0.0031 | 1.96M | -13.89% | n/a | -101.21% |
| BioRestorative Therapies Inc | BRTX | Biotechnology | 0.2799 | 1.94M | 9.25% | n/a | 0.77% |
| Arsanis Inc | ASNS | Biotechnology | 0.3081 | 1.85M | 6.17% | n/a | 252.35% |
| Akari Therapeutics Plc | AKTX | Biotechnology | 0.1301 | 1.58M | -10.65% | n/a | -27.01% |
| Allarity Therapeutics Inc. Common Stock | ALLR | Biotechnology | 1.08 | 1.53M | -1.82% | n/a | 6.68% |
| CARM | CARM | Biotechnology | 0.036 | 1.50M | n/a | 1044.17% | |
| Plus Therapeutics Inc | PSTV | Biotechnology | 0.2479 | 1.46M | 2.82% | n/a | -45.04% |
| ERNA | ERNA | Biotechnology | 0.2657 | 1.44M | -1.59% | n/a | -577.12% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.09 | 1.15M | -2.34% | n/a | 0.00% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.39 | - | Cheaper |
| Ent. to Revenue | 10.02 | - | Cheaper |
| PE Ratio | 0.01 | 41.03 | Cheaper |
| Price to Book | 2.42 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 169.15 | - | Riskier |
| Debt to Equity | 0.42 | -1.23 | Expensive |
| Debt to Assets | 0.19 | 0.25 | Cheaper |
| Market Cap | 2.16M | - | Emerging |